


## L-Kynurenine-<sup>13</sup>C<sub>10</sub> sulfate

<b>Cat. No.:</b>	HY-104026BS
<b>Molecular Formula:</b>	<sup>13</sup> C <sub>10</sub> H <sub>14</sub> N <sub>2</sub> O <sub>7</sub> S
<b>Molecular Weight:</b>	316.22
<b>Target:</b>	Aryl Hydrocarbon Receptor; Endogenous Metabolite
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype <sup>[1][2]</sup> .
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019 Feb;53(2):211-216.
- [2]. Benjamin J Moyer, et al. Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1. *Toxicol Appl Pharmacol*. 2016 Jun 1;300:13-24.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA